your market intelligence analyst
Search Results
266 results
Your search is now limited to «AbbVie» expert search.
Seeking Alpha 08/18/2019 06:53
AbbVie (ABBV) announced that it had received FDA approval for updatacitinib to be marketed as RINVOQ.
More from Seeking Alpha: 08/16/2019 16:47
Humira brought in global revenue of $4.87 billion in the second quarter, but sales have been hit by competition from cheaper rivals in Europe, and AbbVie in June announced a deal to buy Botox-maker Allergan Plc for $63 billion to reduce dependence on the drug.
More from
Investor's Business Daily 08/16/2019 16:25
Shares of AbbVie (ABBV) leapt higher Friday after the Food and Drug Administration approved its new rheumatoid arthritis treatment, known as Rinvoq, — a potential rival to drugs from Eli Lilly (LLY) and Pfizer (PFE.
More from Investor's Business Daily:
ENDPOINTS 08/16/2019 14:53
Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.
More from ENDPOINTS:
FiercePharmaManufacturing 08/16/2019 14:02
The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here.
More from FiercePharmaManufacturing:
PR Newswire 08/16/2019 12:43
For those with limited or no health insurance, AbbVie offers myAbbVie Assist, a patient assistance program that provides RINVOQ to qualifying patients.
More from PR Newswire: 08/13/2019 09:35
We should also point out that AbbVie has a forward PE ratio (price relative to this year’s earnings) of just 7.40, so it is fair to say that a slightly more value-oriented path may be ahead for AbbVie stock in the near term too ...
More from
Korean Biomedical Review 08/07/2019 03:25
The AbbVie-Allergan merger comes at a time when the AbbVie's shares plunged 21 percent in the past six months with its market cap falling to $107.5 billion.
More from Korean Biomedical Review:
PMLiVE 08/06/2019 05:07
AbbVie is gunning for the second indication for its new women’s health product Orilissa, hoping to add uterine fibroids to its FDA approval last year in endometriosis-related pain.
More from PMLiVE:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications